Related Experiment Video
Updated: Jul 9, 2026
06:52
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Targeting MDM2 and MDMX in retinoblastoma
Nikia A Laurie1, Chie-Schin Shih, Chie Schin-Shih
1Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Current Cancer Drug Targets
|November 30, 2007
Summary
Targeted chemotherapy, like nutlin-3 delivered locally, shows promise for treating retinoblastoma (a childhood cancer). This approach improves survival rates, especially in developing nations, by reducing side effects and costs.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- Retinoblastoma is a common infant cancer, with survival rates significantly lower in developing countries due to detection and treatment challenges.
- Systemic chemotherapy for retinoblastoma causes severe side effects in young children.
Purpose of the Study:
- To review recent data on targeted chemotherapy for retinoblastoma.
- To evaluate the potential of local drug delivery for improved treatment outcomes.
Main Methods:
- Summarized recent research on the p53 pathway's role in retinoblastoma.
- Investigated the efficacy of MDM2 inhibitor nutlin-3.
- Assessed subconjunctival delivery of nutlin-3 in preclinical models.
Main Results:
- The p53 pathway is inactivated in 75% of retinoblastoma cases, often due to MDM2 and MDMX gene amplification.
- Nutlin-3 effectively induces p53-mediated cell death in retinoblastoma cells.
- Subconjunctival nutlin-3 demonstrated in vivo efficacy in preclinical retinoblastoma models.
Conclusions:
- Local delivery of targeted chemotherapy, such as subconjunctival nutlin-3, offers a promising treatment strategy for retinoblastoma.
- This approach achieves higher intraocular drug concentrations with fewer systemic side effects.
- Subconjunctival administration may be a cost-effective and less complicated treatment option globally.
Related Concept Videos
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...